|
A Pathway to Evidence-Based Management of IBD
GastroenterologyThe Gastroenterology Learning Pathway, Phase III: Achieving Success in IBD Management
0.75 AMA PRA Category 1 Credit(s) ™
October 30, 2018
The accreditation for this activity has expired.
Primary Audience:
Gastroenterologists and Gastroenterology NPs and PAs
Relevant Terms:
IBD
Gil Y. Melmed, MD, MS
Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA
Bio
Gil Y. Melmed, MD, MS, is the co-director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, CA. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, NY and master of science degree in clinical research from UCLA School of Medicine in Los Angeles, CA. He completed his gastroenterology fellowship at the University of California, Los Angeles, CA. Dr Melmed is board certified in internal medicine and gastroenterology.
Dr Melmed’s research interests include clinical outcomes and quality of care in inflammatory bowel disease (IBD). He has authored or coauthored more than 130 articles in peer-reviewed journals and several book chapters. He is an associate editor of the American Journal of Gastroenterology, an ad hoc reviewer for several journals, and previously a clinical research editor for Inflammatory Bowel Diseases. Dr Melmed has given more than 100 invited lectures and presentations nationally and internationally. He is a committee member of several professional organizations, including the American College of Gastroenterology and the Crohn’s and Colitis Foundation, where he serves as co-chair of the IBD Quality of Care committee. He has led or participated in the development of quality measures for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, and the Canadian Crohn’s and Colitis organizations.
| 1. | Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data | 2. | Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity |
| 3. | Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD | 4. | Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making |
| 1. | Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data |
| 2. | Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity |
| 3. | Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD |
| 4. | Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making |
PHYSICIAN CONTINUING MEDICAL EDUCATION
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Gil Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees).
RMEI Medical Education, LLC
- Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
- Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
- Sharon Powell, has no affiliations with commercial interests to disclose.
AGA Institute
- Monique Dyson, has no affiliations with commercial interests to disclose.
- Sandra Amos, has no affiliations with commercial interests to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 0.75 hour
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.
| COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD! *The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card. Rules and Regulations |
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
